tolvaptan has been researched along with sitagliptin in 2 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (sitagliptin) | Trials (sitagliptin) | Recent Studies (post-2010) (sitagliptin) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 97 | 0 | 70 |
| Protein | Taxonomy | tolvaptan (IC50) | sitagliptin (IC50) |
|---|---|---|---|
| Chain A, Dipeptidyl peptidase IV | Homo sapiens (human) | 0.018 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 0.0255 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.0194 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.0236 | |
| Dipeptidyl peptidase 4 | Mus musculus (house mouse) | 0.046 | |
| Prolyl endopeptidase FAP | Homo sapiens (human) | 2.93 | |
| Dipeptidyl peptidase 8 | Homo sapiens (human) | 0.4715 | |
| Dipeptidyl peptidase 9 | Homo sapiens (human) | 1.539 | |
| Dipeptidyl peptidase 2 | Homo sapiens (human) | 0.022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for tolvaptan and sitagliptin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for tolvaptan and sitagliptin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |